Based in Amsterdam, uniQure N.V. is a biotechnology company developing gene therapies for rare and severe diseases. The company's approved product is HEMGENIX, a gene therapy enabling patients with hemophilia B to produce factor IX protein, thereby reducing bleeding risk. The company is also advancing a pipeline of investigational gene therapies across multiple rare disease indications, including AMT-130 for Huntington's disease (Phase I/II), AMT-260 for mesial temporal lobe epilepsy (Phase I/IIa), AMT-162 for SOD1-amyotrophic lateral sclerosis (Phase I/IIa), and AMT-191 for Fabry disease (Phase I/IIa).
uniQure operates primarily in the United States market. The company has established partnerships to support its development and commercialization efforts, including a licensing agreement with Apic Bio for intrathecal gene therapy development in SOD1-ALS and a development and commercial supply agreement with CSL Behring. Founded in 1998, the company employs approximately 209 full-time staff and maintains a market capitalization of $1.1 billion.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $-3.46 | $-3.46 | +29.7% | |
| 2024 | $-4.92 | $-4.92 | +24.0% | |
| 2023 | $-6.47 | $-6.47 | -138.7% | |
| 2022 | $-2.71 | $-2.71 | -138.5% | |
| 2021 | $7.04 | $7.17 | — | |
| 2020 | — | — | — | |
| 2019 | — | — | — | |
| 2018 | — | — | — | |
| 2017 | — | — | — | |
| 2016 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2025-12-31 | 2026-03-02 | 0001104659-26-021898 | SEC ↗ |
| 2024-12-31 | 2025-02-27 | 0001558370-25-001699 | SEC ↗ |
| 2023-12-31 | 2024-02-28 | 0001558370-24-001915 | SEC ↗ |
| 2022-12-31 | 2023-02-27 | 0001558370-23-002110 | SEC ↗ |
| 2021-12-31 | 2022-02-25 | 0001558370-22-002050 | SEC ↗ |
| 2020-12-31 | 2021-03-01 | 0001558370-21-002186 | SEC ↗ |
| 2019-12-31 | 2020-03-02 | 0001558370-20-001883 | SEC ↗ |
| 2018-12-31 | 2019-02-28 | 0001558370-19-001305 | SEC ↗ |
| 2017-12-31 | 2018-03-14 | 0001558370-18-002042 | SEC ↗ |
| 2016-12-31 | 2017-03-15 | 0001047469-17-001589 | SEC ↗ |